Company intelligence / Profile preview
Harrow
Nashville, Tennessee, United Statesharrow.com ↗
- Ownership
- Public · HROW
- Employees
- ~382
- Development stage
- Other
01
Overview
Harrow has a broad commercial portfolio of FDA-approved and compounded ophthalmic pharmaceuticals for a range of acute and chronic eye diseases. The company’s products are widely used in the U.S. by ophthalmologists and retinal specialists for both surgical procedures and ongoing care. Revenue growth has been strong in recent years as the company expands its product offerings[1][5][6].
- Therapeutic areas
- OphthalmologyImmunologyInfectious Diseases
- Modalities
- Small molecules (ophthalmic drugs)Compounded formulations
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
EyePoint Pharmaceuticals partnership to sell Dexycu steroid product through ImprimisRx[4]No other major partnerships explicitly listed in results.
04
Financials
- Market cap
- $976.2M
- Total revenue
- $272.3M
- Enterprise value
- $1.2B
Beyond the preview
Go deeper on Harrow.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Harrow.